Novartis Said Wednesday That The Fda Has Cleared Its Pcsk9-Targeting Sirna Leqvio (Inclisiran) As An Add-On Therapy To Help Decrease Cholesterol Levels In Certain High-Risk Adults. The Drug, Which Will Be Available In Early January, Is Indicated For Use Along With Maximally Tolerated Statins For Patients With Heterozygous Familial Hypercholesterolaemia (Hefh) Or Clinical Atherosclerotic Cardiovascular Disease (Ascvd) Who Require Additional Lowering Of Ldl Cholesterol."Leqvio Is A Revolutionary Approach
